#United States #San Francisco #RNA Therapies #Charles River #Therna Biosciences

Therna and Charles River Join Forces for RNA Therapeutics Development

In a landmark development in the field of personalized medicine, Therna Biosciences has announced a collaboration with Charles River that aims to advance the creation of single-patient RNA therapeutics tailored for individuals suffering from severe and ultra-rare disorders. This announcement was made public at the Personalized Medicine World Conference held in Silicon Valley, highlighting a growing trend where biotechnology and artificial intelligence converge to enable tailor-made treatments.

Focus on Ultra-Rare Disorders

The collaboration showcases its first two initiatives, focusing on two specific patients—an adult diagnosed with a rapidly progressive, uncommon form of lung fibrosis and a newborn suffering from Lamb-Shaffer Syndrome, an ultra-rare central nervous system disorder. This partnership aims not just to provide customized solutions for these patients but also serves as a proof of concept for the precision of RNA therapeutic design.

Innovation through AI

The core of Therna's approach lies within its advanced AI-enabled RNA design platform. Impressively, the mRNA therapeutic candidate for the adult lung fibrosis patient was generated within just three days, with lab validation completed in under three months. This rapid rate of development is accented by the platform’s capabilities to create mRNA candidates with enhanced durability and specificity, ensuring improved treatment options. Charles River will push the preclinical development of this program, aiming for a swift Investigational New Drug application and subsequent patient dosing later this year.

For the newborn with Lamb-Shaffer Syndrome, Therna is working on designing small antisense oligonucleotides (ASOs) intended to boost gene expression and potentially restore function to a defective gene. Charles River will handle the preclinical testing of these candidate ASOs, highlighting the role of collaboration in navigating complex therapeutic processes.

Statement from Leadership

Dr. Nazli Azimi, CEO of Therna, emphasized the company’s commitment to revolutionizing RNA as a treatment modality, citing: "Therna was founded on the belief that RNA can be programmed with precision, speed, and predictability. This collaboration not only affirms our approach but also accelerates the availability of advanced therapies for patients in urgent need."

Furthermore, Dr. Roxana Redis of Charles River expressed pride in the partnership, noting that the capability to transform personalized therapeutic concepts into preclinical testing rapidly reflects the potential of Therna’s platform in developing innovative RNA therapies.

The Bigger Picture: Expanding the RNA Therapeutic Field

The initiative is more than just patient-specific; it’s about refining the understanding of RNA biology as well. Each single-patient program can yield new biological and functional data that continuously contribute to the machine learning models Therna employs. The goal is to expedite the development of a wider array of RNA medicines that can address various diseases. This feature is particularly significant for conditions that lack sufficient patient populations for traditional clinical trials, thus expanding the horizons of research and development in this niche area.

Therna's commitment involves not just partnering with industry leaders like Charles River but also engaging closely with regulatory bodies to ensure rigorous preclinical validation is met, all while tailoring treatment assessments for individual patients.

Therna’s headquarters in San Francisco underscores the company's strategic positioning at the heart of biotech innovations, merging cutting-edge research with real-world applications in disease treatment. The collaboration's focus on ultra-rare diseases reflects a tangible shift towards addressing neglected territories within medical research, offering hope for patients where options are severely limited.

As personalized medicine continues to evolve, partnerships like that of Therna and Charles River stand at the forefront, illustrating how targeted and innovative approaches can not only create solutions for individual patients but also pave the way for significant advancements in the field of RNA therapeutics. Through collaborative efforts, the potential to revolutionize the treatment landscape for ultra-rare conditions could finally become a reality.